PMID- 30584321
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with 
      pretreated advanced non-small-cell lung cancer: a meta-analysis.
PG  - 8623-8632
LID - 10.2147/OTT.S181413 [doi]
AB  - BACKGROUND: PD1/PDL1 blockade is a promising treatment for patients with 
      non-small-cell lung cancer (NSCLC). Here, we employed meta-analysis to evaluate 
      the efficacy and safety of PD1/PDL1 blockades for previously treated NSCLC 
      patients. METHODS: Randomized clinical trials were retrieved by searching 
      electronic databases. Data for HRs, 95% CIs for overall survival (OS), 
      progression-free survival (PFS), and adverse events (AEs) were extracted and 
      pooled. RESULTS: A total of five randomized controlled trials including 2,910 
      patients were included in this meta-analysis. Pooled HRs (95% CI) were 0.71 
      (0.63-0.79, P<0.0001) for OS and 0.86 (0.73-1.02) for PFS. In the subgroup 
      analysis, the pooled HR (95% CI) for PFS was 0.82 (0.75-0.91, P<0.0001) in 
      patients with high PDL1 expression, but no significant difference was seen in 
      patients with low expression (0.97 [0.76-1.24], P=0.82). The pooled RR for 
      treatment-related AEs of all grades was 0.32 (0.27-0.38, P<0.00001) compared with 
      the docetaxel arm, while that for grade 3-5 treatment-related AEs in the 
      PD1/PDL1-blockade arm was 0.16 (0.10-0.27, P<0.00001). CONCLUSION: PD1/PDL1 
      blockades enhanced OS and PFS and led to lower risk of AEs in NSCLC patients. 
      Smoking history and wild-type EGFR were associated with extended OS.
FAU - Liu, Jixiang
AU  - Liu J
AD  - Department of Respiratory Medicine, The First Affiliated Hospital, Nanchang 
      University, Nanchang, China, ganxin1207@126.com.
FAU - Zhong, Yulan
AU  - Zhong Y
AD  - Department of Respiratory Medicine, The First Affiliated Hospital, Nanchang 
      University, Nanchang, China, ganxin1207@126.com.
FAU - Peng, Shanshan
AU  - Peng S
AD  - Department of Respiratory Medicine, The First Affiliated Hospital, Nanchang 
      University, Nanchang, China, ganxin1207@126.com.
FAU - Zhou, Xiangxiang
AU  - Zhou X
AD  - Department of Respiratory Medicine, The First Affiliated Hospital, Nanchang 
      University, Nanchang, China, ganxin1207@126.com.
FAU - Gan, Xin
AU  - Gan X
AD  - Department of Respiratory Medicine, The First Affiliated Hospital, Nanchang 
      University, Nanchang, China, ganxin1207@126.com.
LA  - eng
PT  - Journal Article
DEP - 20181203
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6284541
OTO - NOTNLM
OT  - PD1
OT  - PDL1
OT  - checkpoint immunologic treatments
OT  - meta-analysis
OT  - non-small-cell lung cancer
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/12/26 06:00
MHDA- 2018/12/26 06:01
PMCR- 2018/12/03
CRDT- 2018/12/26 06:00
PHST- 2018/12/26 06:00 [entrez]
PHST- 2018/12/26 06:00 [pubmed]
PHST- 2018/12/26 06:01 [medline]
PHST- 2018/12/03 00:00 [pmc-release]
AID - ott-11-8623 [pii]
AID - 10.2147/OTT.S181413 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Dec 3;11:8623-8632. doi: 10.2147/OTT.S181413. eCollection 
      2018.